The novel peptide NbPPI1 identified from Nicotiana benthamiana triggers immune responses and enhances resistance against Phytophthora pathogens

Author(s):  
Qujiang Wen ◽  
Manli Sun ◽  
Xianglan Kong ◽  
Yang Yang ◽  
Qiang Zhang ◽  
...  
Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1298
Author(s):  
Raina K. Plowright ◽  
Peter J. Hudson

Pandemics are a consequence of a series of processes that span scales from viral biology at 10−9 m to global transmission at 106 m. The pathogen passes from one host species to another through a sequence of events that starts with an infected reservoir host and entails interspecific contact, innate immune responses, receptor protein structure within the potential host, and the global spread of the novel pathogen through the naive host population. Each event presents a potential barrier to the onward passage of the virus and should be characterized with an integrated transdisciplinary approach. Epidemic control is based on the prevention of exposure, infection, and disease. However, the ultimate pandemic prevention is prevention of the spillover event itself. Here, we focus on the potential for preventing the spillover of henipaviruses, a group of viruses derived from bats that frequently cross species barriers, incur high human mortality, and are transmitted among humans via stuttering chains. We outline the transdisciplinary approach needed to prevent the spillover process and, therefore, future pandemics.


Pharmaceutics ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 1859
Author(s):  
Yunys Pérez-Betancourt ◽  
Péricles Marques Araujo ◽  
Bianca de Carvalho Lins Fernandes Távora ◽  
Daniele Rodrigues Pereira ◽  
Eliana Lima Faquim-Mauro ◽  
...  

Nanostructures have been of paramount importance for developing immunoadjuvants. They must be cationic and non-cytotoxic, easily assembling with usually oppositely charged antigens such as proteins, haptens or nucleic acids for use in vaccines. We obtained optimal hybrid nanoparticles (NPs) from the biocompatible polymer poly(methyl methacrylate) (PMMA) and the cationic lipid dioctadecyl dimethyl ammonium bromide (DODAB) by emulsion polymerization of methyl methacrylate (MMA) in the presence of DODAB. NPs adsorbed ovalbumin (OVA) as a model antigen and we determined their adjuvant properties. Interestingly, they elicited high double immune responses of the cellular and humoral types overcoming the poor biocompatibility of DODAB-based adjuvants of the bilayer type. The results suggested that the novel adjuvant would be possibly of use in a variety of vaccines.


2019 ◽  
Vol 14 (12) ◽  
pp. 1682220 ◽  
Author(s):  
Xuejiao Lei ◽  
Xia Lan ◽  
Wenxiu Ye ◽  
Yunxiao Liu ◽  
Shiren Song ◽  
...  

2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Jiang Xiang ◽  
Xinlong Li ◽  
Ling Yin ◽  
Yunxiao Liu ◽  
Yali Zhang ◽  
...  

Vaccine ◽  
2008 ◽  
Vol 26 (27-28) ◽  
pp. 3461-3468 ◽  
Author(s):  
Karin Riedl ◽  
Rosemarie Riedl ◽  
Alexander von Gabain ◽  
Eszter Nagy ◽  
Karen Lingnau

2021 ◽  
Author(s):  
Anjali Priyadarshini ◽  
Archana Gupta ◽  
Manoj Kumar Yadav ◽  
Arpana Vibhuti ◽  
Ramendra Pati Pandey ◽  
...  

Tuberculosis and Covid-19 infection measure two quite different diseases- TB is caused by a sort of bacterium whereas Covid-19 is caused by a virus. However, the BCG immunizing agent would possibly facilitate individuals build immune responses to things aside from TB, inflicting "off-target effects," In different words, in run format, individuals started learning positive in obtaining the immunizing agent that had nothing to try and do with TB, several studies showed however the BCG immunizing agent affects individuals with kind one although the precise mechanism for these off-target effects of the BCG immunizing agent is not clear, it's believed that the immunizing agent will cause a nonspecific boost of the reaction. There is presently no immunizing agent or treatments approved by the United States of America Food and Drug Administration for the novel coronavirus. BCG is usually innocuous with the most facet impact the event of inflammation at the positioning of injection. Supported by these observations BCG so emerges as a possible candidate for the development of innate and adjustive reactions which can be non-specifically taking care of mycobacterium and different infectious agents against that vaccine remains not on the market.


2021 ◽  
Vol 2 (3) ◽  
pp. 01-06
Author(s):  
Prabir Mandal

Viruses mutate all the time, and the coronavirus that causes COVID-19 is no exception. As new variants of the COVID-19 emerge, a slew of new studies suggest that some may be able to evade immune responses triggered by a previous infection or by a vaccine. The novel variants of SARS-CoV-2 including those seen in the UK (2OI/5O1Y.V1/B.1.1.7), South Africa (2OH/5O1Y.V2/B.1.351), Brazil (P.1/2OJ/5O1Y.V3/B.1.1.248) have emerged with the concern of increased infectivity and virulence. Scientists are working to learn more about the characteristics of these strains whether they could cause more severe illness, and whether currently authorized vaccines will protect people against them. All viruses naturally mutate and evolve over time. For example, flu virus change often, which is why doctors recommend that you get a flu shot every year. Various mRNA vaccine platforms have been developed in recent years and validated in studies of immunogenicity and efficacy.


Biomolecules ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1254
Author(s):  
Naiara Naiana Dejani ◽  
Hatem A. Elshabrawy ◽  
Carlos da Silva Maia Bezerra Filho ◽  
Damião Pergentino de Sousa

In 2019, COVID-19 emerged as a severe respiratory disease that is caused by the novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The disease has been associated with high mortality rate, especially in patients with comorbidities such as diabetes, cardiovascular and kidney diseases. This could be attributed to dysregulated immune responses and severe systemic inflammation in COVID-19 patients. The use of effective antiviral drugs against SARS-CoV-2 and modulation of the immune responses could be a potential therapeutic strategy for COVID-19. Studies have shown that natural phenolic compounds have several pharmacological properties, including anticoronavirus and immunomodulatory activities. Therefore, this review discusses the dual action of these natural products from the perspective of applicability at COVID-19.


2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Hafiz Muhammad Khalid Abbas ◽  
Jingshu Xiang ◽  
Zahoor Ahmad ◽  
Lilin Wang ◽  
Wubei Dong

2010 ◽  
Vol 84 (16) ◽  
pp. 7943-7952 ◽  
Author(s):  
R. Bodewes ◽  
J. H. C. M. Kreijtz ◽  
G. van Amerongen ◽  
M. M. Geelhoed-Mieras ◽  
R. J. Verburgh ◽  
...  

ABSTRACT Highly pathogenic avian influenza A viruses of the H5N1 subtype continue to circulate in poultry, and zoonotic transmissions are reported frequently. Since a pandemic caused by these highly pathogenic viruses is still feared, there is interest in the development of influenza A/H5N1 virus vaccines that can protect humans against infection, preferably after a single vaccination with a low dose of antigen. Here we describe the induction of humoral and cellular immune responses in ferrets after vaccination with a cell culture-derived whole inactivated influenza A virus vaccine in combination with the novel adjuvant CoVaccine HT. The addition of CoVaccine HT to the influenza A virus vaccine increased antibody responses to homologous and heterologous influenza A/H5N1 viruses and increased virus-specific cell-mediated immune responses. Ferrets vaccinated once with a whole-virus equivalent of 3.8 μg hemagglutinin (HA) and CoVaccine HT were protected against homologous challenge infection with influenza virus A/VN/1194/04. Furthermore, ferrets vaccinated once with the same vaccine/adjuvant combination were partially protected against infection with a heterologous virus derived from clade 2.1 of H5N1 influenza viruses. Thus, the use of the novel adjuvant CoVaccine HT with cell culture-derived inactivated influenza A/H5N1 virus antigen is a promising and dose-sparing vaccine approach warranting further clinical evaluation.


Sign in / Sign up

Export Citation Format

Share Document